Novartis: Thalassemia trials

The registry lists 21 Thalassemia studies with Novartis as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 9Phase 3 5Phase 4 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible TabletCompletedNCT02993224Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)CompletedNCT02125877Phase 2Results posted
• Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.CompletedNCT02049450Phase 2Results posted
• An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)CompletedNCT01736540Phase 4Results posted
• Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent ThalassemiaCompletedNCT01709838Phase 4Results posted
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadCompletedNCT00235391Phase 3Results posted
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
• Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent ThalassemiaWithdrawnNCT02069886Phase 4
• Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High DosesWithdrawnNCT01948817Phase 2
• This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
• A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe ToxicityCompletedNCT01044186Phase 2
• Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 MsecCompletedNCT00879242Phase 2
• Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00560820Phase 1
• Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal EventsCompletedNCT00346242Phase 4
• A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 3
• A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisCompletedNCT00171171Phase 3
• Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 3